Our Products

We focus on developing technologies targeting unmet medical challenges such as oncology and infectious diseases by means of nanotechnology

ON MARKET

Paclitaxel protein boud particles; Nab-Placlitaxel

Nanoparticle albumin-bound Paclitaxel or Nab-Paclitaxel is an injectable formulation used as standard of care for breast, lung and pancreatic cancer. Formulation of Paclitaxel as albumin nanoparticles improves the toxicity profile (when compared with previous formulations) allowing for higher doses during treatment. Paclitaxel mode of action prevents normal breakdown of cancerous cells microtubules during division.

Treatment

Indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease

Technology

Nanoparticles, Lyoph. Inject.

Reference product

Abraxane™ (Celgene)

ON MARKET

Octreotide depot

Octreotide is a synthetic peptide that mimics natural somatostatin although with a more potent inhibitor activity towards growth hormone, glucagon, and insulin.

Treatment

Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid stimulating hormone (thyrotropinoma), diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors.

Technology

PLGA microspheres, Lyoph. Inject.

Reference product

Sandostatin™Lar Depot (Novartis)

ON MARKET

Doxonax

Pegylated Liposomal Doxorubicin is a polyethylene glycol coated liposome-encapsulated form of doxorubicin used to treat cancer. It was the first nanomedicine approved by FDA. This formulation was developed to overcome clearance of previous liposomal formulations (which addressed doxorubicin traditional formulation´s toxic side effects). Doxorubicin is actively loaded using a transmembrane ionic gradient.

Treatment

Used to treat breast cancer, ovarian cancer, myeloma, and HIV-related Kaposi's sarcoma. Also used as second line treatment for other types of cancer.

Technology

Pegylated liposome, Injectable solution.

Reference product

Caelyx™ (Schering Plough)

ON MARKET

Amphotericin B Liposome

Liposomal Amphotericin B is comprised of Amphotericin B drug molecules intercalated in single bilipid layer liposomes. It is formulated as a sterile, non-pyrogenic lyophilized powder for reconstitution for intravenous infusion.

Treatment

Used to treat fungal infections such as cryptococcal meningitis and visceral leishmaniasis

Technology

Liposomes, Lyoph. Inject

Reference product

Ambisome™ (Gilead)

ON MARKET

Leuprolide depot 1 and 3 months

Leuprolide is a synthetic peptide analog of the naturally occurring gonadotrophin releasing hormone with increased activity. This injectable formulation relies on polymer microspheres to improve release profile, reducing application frequency to once every 1 or 3 months instead of daily applications. 

Treatment

Used in the treatment of hormone-responsive cancers such as prostate cancer and breast cancer. It may also be used for estrogen-dependent conditions such as endometriosis or uterine fibroids

Technology

PLGA microspheres, Lyoph. Inject

Reference product

Lupron™ (Abbott)

Pipeline

We are working on the medical challenges developing technologies to fight cancer and infections diseases. The more promising technologies are in licensed and developed in our labs and being transformed into nano medicines.

ON MARKET

Paclitaxel protein boud particles; Nab-Placlitaxel

Nanoparticle albumin-bound Paclitaxel or Nab-Paclitaxel is an injectable formulation used as standard of care for breast, lung and pancreatic cancer. Formulation of Paclitaxel as albumin nanoparticles improves the toxicity profile (when compared with previous formulations) allowing for higher doses during treatment. Paclitaxel mode of action prevents normal breakdown of cancerous cells microtubules during division.

Treatment

Indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease

Technology

Nanoparticles, Lyoph. Inject.

Reference product

Abraxane™ (Celgene)

ON MARKET

Octreotide depot

Octreotide is a synthetic peptide that mimics natural somatostatin although with a more potent inhibitor activity towards growth hormone, glucagon, and insulin.

Treatment

Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid stimulating hormone (thyrotropinoma), diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors.

Technology

PLGA microspheres, Lyoph. Inject.

Reference product

Sandostatin™Lar Depot (Novartis)

ON MARKET

Doxonax

Pegylated Liposomal Doxorubicin is a polyethylene glycol coated liposome-encapsulated form of doxorubicin used to treat cancer. It was the first nanomedicine approved by FDA. This formulation was developed to overcome clearance of previous liposomal formulations (which addressed doxorubicin traditional formulation´s toxic side effects). Doxorubicin is actively loaded using a transmembrane ionic gradient.

Treatment

Used to treat breast cancer, ovarian cancer, myeloma, and HIV-related Kaposi's sarcoma. Also used as second line treatment for other types of cancer.

Technology

Pegylated liposome, Injectable solution.

Reference product

Caelyx™ (Schering Plough)

ON MARKET

Amphotericin B Liposome

Liposomal Amphotericin B is comprised of Amphotericin B drug molecules intercalated in single bilipid layer liposomes. It is formulated as a sterile, non-pyrogenic lyophilized powder for reconstitution for intravenous infusion.

Treatment

Used to treat fungal infections such as cryptococcal meningitis and visceral leishmaniasis

Technology

Liposomes, Lyoph. Inject

Reference product

Ambisome™ (Gilead)

ON MARKET

Leuprolide depot 1 and 3 months

Leuprolide is a synthetic peptide analog of the naturally occurring gonadotrophin releasing hormone with increased activity. This injectable formulation relies on polymer microspheres to improve release profile, reducing application frequency to once every 1 or 3 months instead of daily applications. 

Treatment

Used in the treatment of hormone-responsive cancers such as prostate cancer and breast cancer. It may also be used for estrogen-dependent conditions such as endometriosis or uterine fibroids

Technology

PLGA microspheres, Lyoph. Inject

Reference product

Lupron™ (Abbott)

Nanomedicine

Nanoparticle therapeutic carriers based medicine

Nanox’s drug carriers enhance the in-vivo efficiency of many drugs, especially anti-cancer drugs which are passively targeted to tumor through enhanced permeability and retention effect, making them ideally suited for the delivery of chemotherapeutics. Nanox portfolio includes many nanoparticle delivery systems developed for cancer therapy, including organic and inorganic active principles.